Stocks Featured in Zacks Equity Research Analyst Blog

Strategic Insights -

Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Recently featured stocks include Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), Pfizer (NYSE: PFE), Cognizant Technology Solutions Corp. (NASDAQ: CTSH), Neurocrine Biosciences, Inc. (NASDAQ: NBIX), and Coca-Cola FEMSA S.A. de C.V. (NYSE: KOF). These companies have shown promising results in the first quarter of 2009, with some experiencing a significant increase in revenues and others posting solid results despite challenging economic conditions.

Key Takeaways:

  • Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) reported a 28% increase in total revenues for the first quarter of 2009, with $32.5 million in U.S. sales of Testim, up 20% year-over-year.
  • Cognizant Technology Solutions Corp. (NASDAQ: CTSH) posted fiscal Q1 results with revenues of $746 million, ahead of Zacks' estimate of $734 million, although down 1% quarter-over-quarter.
  • Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported the results of the Petal-602 study, which showed no apparent effect from baseline in the elagolix treatment arms on bone mineral density (BMD) after 12 months of treatment.
  • Coca-Cola FEMSA S.A. de C.V. (NYSE: KOF) posted positive operating results for the first quarter of 2009, with impressive results in the Mercosur and Latincentro division.
  • Zacks Equity Research provides continuous coverage for 1,150 publicly traded stocks, with analysts organized by industry to provide keen insights into company profits and stock performance.

Statistics:

  • Auxilium Pharmaceuticals, Inc. incurred a $2.0 million lower-than-expected sales of Testim.
  • Cognizant Technology Solutions Corp. posted a non-GAAP gross margin of 20.2% and GAAP EPS of $0.38.
  • Neurocrine Biosciences, Inc. reported a mean change in BMD of +0.19% for the spine and -0.28% for the femur after 12 months of treatment with 150mg elagolix.
  • Coca-Cola FEMSA S.A. de C.V. witnessed a 2% sequential decline in revenues from the banking vertical.
  • Zacks Equity Research has a proprietary stock picking system, the Zacks Rank, which has outperformed the market by nearly a 3 to 1 margin.

Sources:

  • Zacks.com
  • Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) financial results for the first quarter 2009
  • Cognizant Technology Solutions Corp. (NASDAQ: CTSH) fiscal Q1 results
  • Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Petal-602 study results
  • Coca-Cola FEMSA S.A. de C.V. (NYSE: KOF) first quarter 2009 operating results
  • Zacks.com
  • Zacks Investment Research, Inc. website